Evaxion A/S (EVAX)
Market Cap | 14.53M |
Revenue (ttm) | 3.29M |
Net Income (ttm) | -13.34M |
Shares Out | 6.32M |
EPS (ttm) | -6.63 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 168,291 |
Open | 2.630 |
Previous Close | 2.630 |
Day's Range | 2.171 - 2.640 |
52-Week Range | 1.200 - 20.000 |
Beta | -0.23 |
Analysts | Strong Buy |
Price Target | 10.00 (+334.78%) |
Earnings Date | May 27, 2025 |
About EVAX
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vacci... [Read more]
Financial Performance
In 2024, Evaxion's revenue was $3.34 million, an increase of 4480.82% compared to the previous year's $73,000. Losses were -$10.57 million, -52.24% less than in 2023.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for EVAX stock is "Strong Buy." The 12-month stock price forecast is $10.0, which is an increase of 334.78% from the latest price.
News

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript
Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call May 27, 2025 8:30 PM ET Company Participants Christian Kanstrup - CEO Birgitte Rono - Chief Scientific Officer Thomas Schmidt - CFO Conferen...

Evaxion announces business update and first quarter 2025 financial results
COPENHAGEN, Denmark, May 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and an...

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025
Evaxion has demonstrated impressive in-house capabilities for discovering and developing vaccine candidates for both infectious diseases and oncology indications. Partnership with MSD, albeit heavily ...

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025
COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update ...

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, May 22, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has dosed the first patient in ...

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting
COPENHAGEN, Denmark, April 28, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data un...

Evaxion to present at World Vaccine Congress
COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will give two present...

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript
Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Conference Call April 1, 2025 8:30 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rønø - Chief Scientific Officer Thomas S...

Evaxion to announce business update and full year 2024 financial results on April 1, 2025
COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a busine...

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting
COPENHAGEN, Denmark, March 25, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present new data...

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package
COPENHAGEN, Denmark, February 25, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will further enhan...

Evaxion announces closing of $10.8 million public offering
COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the...

Evaxion announces pricing of $10.8 million public offering
COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the...

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement
COPENHAGEN, Denmark, January 28, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has received notice...

Evaxion announces completion of ADS ratio change
COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, to...

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change
COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced tha...

Evaxion announces plan to implement ADS ratio change
COPENHAGEN, Denmark, December 30, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced th...

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new posi...

Evaxion announces business update and third quarter 2024 financial results
COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business u...

Evaxion to announce business update and third quarter 2024 financial results on October 31
COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a busi...

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials
COPENHAGEN, Denmark, October 9, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has now evidence fro...

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
COPENHAGEN, Denmark, October 3, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, continues to gather ...

Evaxion Biotech Partners With Merck To Expand Vaccine Development
Evaxion Biotech A/S EVAX inked an option and licensing deal with Merck & Co., Inc MRK for two preclinical vaccine candidates.

Evaxion significantly expands vaccine development collaboration with MSD
COPENHAGEN, Denmark, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, tod...

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
COPENHAGEN, Denmark, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, lau...